NCT03537157View on ClinicalTrials.gov

A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention

PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

July 15, 2020

Study Completion Date

July 29, 2020

Conditions
Crohn Disease
Interventions
DRUG

Rifaximin delayed release tablets

Active intervention

OTHER

Placebo

Comparator placebo

Trial Locations (1)

20089

Humanitas Clinical Research Center, Rozzano

Sponsors

Lead Sponsor

Alfasigma S.p.A.

Collaborators (1)

Cromsource
All Listed Sponsors
collaborator

Cromsource

INDUSTRY

lead

Alfasigma S.p.A.

INDUSTRY